The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at higher risk of severe disease, but will require vaccine makers to conduct major new clinical trials before approving them for wider use.

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company’s COVID-19 vaccine,

WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by pledging to work within the decades-old federal system for approval and use of vaccines. Yet his regulators are promising big changes that cloud the outlook for what shots might even be available.

Health-related headlines include Mexico's suspension of poultry imports from Brazil due to bird flu, promising results from new HIV vaccine trials, and the FDA's conditional approval of Novavax's COVID-19 vaccine.

Coinbase Global (COIN) will begin trading on the S&P 500 (^GSPC) effective today, replacing Discover Financial Services (DFS) on the exchange. The US Food and Drug Administration (FDA) approves Novavax's (NVAX) COVID-19 vaccine,

In a major policy shift, federal health officials anticipate the shots will be made available to adults 65 and older as well as children and younger adults who have one or more risk factors that make them more vulnerable to severe COVID-19.